3rd Quarter - Report
CAPITOL COUNSEL LLC for ALNYLAM PHARMACEUTICALS, INC.
Firm
Income
$30,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Issues regarding FDA guidance on Platform Technology Platform Technology Designation Program for Drug Development. PDUFA reauthorization, Clinical Trial / IND reform.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JEFFREY CARROLL | — |
| JOHN MARTIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.